Floatz logo

ft538

Myeloid Leukemia

Masonic Cancer Center, University of MinnesotaPhase 1Active
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
M.D. Anderson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Actinium Pharmaceuticals
Phase 2/3BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 2BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 3BB
Rapamycin
Masonic Cancer Center, University of Minnesota
Phase 2BB

View all 50 →

Same molecule, other indications

ft538 is also rated in:

monocytic leukemiaDormant
D
Indicative ·
29 / 100
View asset →
acute myeloid leukemiaDormant
D
Indicative ·
27 / 100
View asset →
peritoneum cancerDormant
D
Indicative ·
27 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →